We are live on ! Find out more
LAB icon

Standard BioTools
LAB

145 hedge funds and large institutions have $391M invested in Standard BioTools in 2020 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 54 increasing their positions, 32 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

101% more call options, than puts

Call options by funds: $5.23M | Put options by funds: $2.6M

69% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 32

41% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 27

8% more funds holding

Funds holding: 134 → 145 (+11)

4.66% less ownership

Funds ownership: 92.76% → 88.1% (-4.7%)

17% less capital invested

Capital invested by funds: $472M → $391M (-$80.9M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
145
Holders Change
+11
Holders Change %
+8.21%
% of All Funds
2.57%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
38
Increased
54
Reduced
32
Closed
27
Calls
$5.23M
Puts
$2.6M
Net Calls
+$2.63M
Net Calls Change
-$2.6M

Top Buyers

1
ICM
Indaba Capital Management
California
+$10.3M
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$3.84M
3
ACM
Asymmetry Capital Management
California
+$3.72M
4
PCMI
Paradigm Capital Management Inc
New York
+$3.56M
5
Two Sigma Investments
Two Sigma Investments
New York
+$3.45M

Top Sellers

1
Invesco
Invesco
Georgia
-$13.8M
2
EP
Eversept Partners
New York
-$9.68M
3
Renaissance Technologies
Renaissance Technologies
New York
-$9.61M
4
Millennium Management
Millennium Management
New York
-$9.26M
5
PVI
Pura Vida Investments
New York
-$6.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$33.5M +$1.39M +210,992 +4%
ICM
2
Indaba Capital Management
California
$33.2M +$10.3M +1,566,848 +40%
Primecap Management
3
Primecap Management
California
$32.6M -$1.43M -218,100 -4%
Neuberger Berman Group
4
Neuberger Berman Group
New York
$27.8M +$1.85M +281,945 +6%
O
5
OrbiMed
New York
$23.4M +$2.22M +338,643 +10%
Vanguard Group
6
Vanguard Group
Pennsylvania
$20.9M -$348K -52,965 -2%
Fidelity Investments
7
Fidelity Investments
Massachusetts
$17.7M -$420K -63,910 -2%
AI
8
Atom Investors
Texas
$17.5M -$1.93M -294,400 -9%
Millennium Management
9
Millennium Management
New York
$9.98M -$9.26M -1,409,094 -46%
ACM
10
Asymmetry Capital Management
California
$9.27M +$3.72M +566,746 +58%
PCMI
11
Paradigm Capital Management Inc
New York
$9.16M +$3.56M +542,000 +55%
State Street
12
State Street
Massachusetts
$7.89M +$448K +68,132 +5%
Marshall Wace
13
Marshall Wace
United Kingdom
$7.67M +$2.88M +438,687 +52%
TM
14
Tikvah Management
North Carolina
$7.5M – – –
NIM
15
Needham Investment Management
New York
$7.5M +$3.09M +470,000 +60%
JP Morgan Chase
16
JP Morgan Chase
New York
$7.28M +$232K +35,329 +3%
N
17
Nuveen
North Carolina
$7.18M +$1.07M +163,618 +16%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$6.84M +$319K +48,574 +4%
PHS
19
PFM Health Sciences
California
$6.34M – – –
Alyeska Investment Group
20
Alyeska Investment Group
Illinois
$5.32M +$2.13M +323,567 +58%
Two Sigma Advisers
21
Two Sigma Advisers
New York
$5.22M +$3.84M +584,274 +204%
Northern Trust
22
Northern Trust
Illinois
$5.21M +$32.5K +4,948 +0.6%
GCM
23
Glenview Capital Management
New York
$4.86M – – –
Renaissance Technologies
24
Renaissance Technologies
New York
$4.47M -$9.61M -1,462,900 -66%
D.E. Shaw & Co
25
D.E. Shaw & Co
New York
$4.15M +$2.6M +395,827 +134%
1
2 3 4 5

LAB Hedge Fund Activity: Q4 2020 in Review

145 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q4 2020, worth a combined $391M — down 17% from $472M a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new LAB positions and 27 closed out — a net gain of 11 holders — while 54 added to existing stakes and 32 trimmed.

The largest buyer was Indaba Capital Management, adding an estimated $10.3M. The largest seller was Invesco, cutting an estimated $13.8M.

  • 145 institutional investors held Standard BioTools (LAB) as of Q4 2020, up from 134 in Q3 2020.
  • Funds reported $391M of Standard BioTools stock for Q4 2020, down 17% quarter-over-quarter.
  • 38 funds opened new Standard BioTools positions in Q4 2020 and 27 closed out, a net change of +11 holders.
  • The largest Standard BioTools buyer in Q4 2020 was Indaba Capital Management, an estimated $10.3M added.
  • The largest Standard BioTools seller in Q4 2020 was Invesco, an estimated $13.8M sold.

Based on aggregated 13F filings for Q4 2020.